Skip to main content
Top
Published in: Annals of Nuclear Medicine 5/2009

01-07-2009 | Original Article

Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer

Authors: Aytekin Guven, Serpil Salman, Harika Boztepe, Sema Yarman, Refik Tanakol, Halil Azizlerli, Faruk Alagol

Published in: Annals of Nuclear Medicine | Issue 5/2009

Login to get access

Abstract

Objective

The study aimed to investigate the effect of high dose radioactive iodine (RAI) on parathyroid function in patients with differentiated thyroid cancer.

Methods

Nineteen patients (8 men/11 women, age 46.5 ± 13.2 years) undergoing RAI for thyroid remnant ablation were enrolled in the study. The biochemical parameters related to parathyroid function [serum calcium (Ca), phosphate (P), creatinine (Cr), alkaline phosphatase (ALP), intact parathyroid hormone (iPTH), urinary Ca, cAMP concentrations and the maximum tubular capacity for phosphate per unit volume of glomerular filtrate (TmP/GFR)] were evaluated at baseline and at the 1st, 3rd, 6th and 12th months of RAI administration. SPSS 15.0 was used for statistical analysis.

Results

For all patients, thyroid-stimulating hormone levels were >30 U/ml at baseline and <0.1 U/ml at the following visits. Serum iPTH levels were decreased significantly at the 6th month and reached basal levels at the 12th month (baseline vs. 6th p = 0.027, 1st vs. 6th p = 0.011, 3rd vs. 6th p = 0.047, 3rd vs. 12th p = 0.014, 6th vs. 12th p = 0.001). At the 6th month, P and TmP/GFR levels were higher (p = 0.036, 0.017, respectively), and urinary cAMP measurements were lower (p = 0.020) compared to those of the 1st month. No difference was detected concerning the other parameters. Serum Ca levels decreased below 2.1 mmol/l in several patients (n = 5 at 1st month, n = 4 at 3rd month, n = 8 at 6th month and n = 3 at 12th month) without clinical symptoms.

Conclusions

The study indicated a transient decline in PTH levels at the 6th month following RAI therapy. Although this decrease did not cause symptoms in any of the present cases, this pattern might be important especially in individuals with diminished parathyroid background.
Literature
1.
go back to reference Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.PubMedCrossRef Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.PubMedCrossRef
2.
go back to reference Christensson T. Hyperparathyroidism and radiation therapy. Ann Intern Med. 1978;89:216–7.PubMed Christensson T. Hyperparathyroidism and radiation therapy. Ann Intern Med. 1978;89:216–7.PubMed
3.
go back to reference Russ JE, Scalon EF, Sener SF. Parathyroid adenomas following irradiation. Cancer. 1979;43:1078–83.PubMedCrossRef Russ JE, Scalon EF, Sener SF. Parathyroid adenomas following irradiation. Cancer. 1979;43:1078–83.PubMedCrossRef
4.
go back to reference Rao SD, Frame B, Miller MJ, Kleerekoper M, Block MA, Parfitt AM. Hyperparathyroidism following head and neck irradiation. Arch Intern Med. 1980;140:205–7.PubMedCrossRef Rao SD, Frame B, Miller MJ, Kleerekoper M, Block MA, Parfitt AM. Hyperparathyroidism following head and neck irradiation. Arch Intern Med. 1980;140:205–7.PubMedCrossRef
5.
go back to reference Stephen AE, Chen KT, Milas MM, Siperstein AE. The coming of age of radiation-induced hyperparathyroidism: evolving patterns of thyroid and parathyroid disease after head and neck radiation. Surgery. 2004;136:1143–53.PubMedCrossRef Stephen AE, Chen KT, Milas MM, Siperstein AE. The coming of age of radiation-induced hyperparathyroidism: evolving patterns of thyroid and parathyroid disease after head and neck radiation. Surgery. 2004;136:1143–53.PubMedCrossRef
6.
go back to reference Eipe J, Johnson SA, Kiamko RT, Bronsky D. Hypoparathyroidism following 131-I therapy for hyperthyroidism. Arch Intern Med. 1968;121:270–2.PubMedCrossRef Eipe J, Johnson SA, Kiamko RT, Bronsky D. Hypoparathyroidism following 131-I therapy for hyperthyroidism. Arch Intern Med. 1968;121:270–2.PubMedCrossRef
7.
go back to reference Fulop M. Hypoparathyroidism after 131 I therapy. Ann Intern Med. 1971;75:808.PubMed Fulop M. Hypoparathyroidism after 131 I therapy. Ann Intern Med. 1971;75:808.PubMed
8.
go back to reference Orme MC, Conolly ME. Hypoparathyroidism after iodine-131 treatment of thyrotoxicosis. Ann Intern Med. 1971;75:136–7.PubMed Orme MC, Conolly ME. Hypoparathyroidism after iodine-131 treatment of thyrotoxicosis. Ann Intern Med. 1971;75:136–7.PubMed
9.
go back to reference Better OS, Garty J, Brautbar N, Barzilai D. Diminished functional parathyroid reserve following I-131 treatment for hyperthyroidism. Isr J Med Sci. 1969;5:419–522.PubMed Better OS, Garty J, Brautbar N, Barzilai D. Diminished functional parathyroid reserve following I-131 treatment for hyperthyroidism. Isr J Med Sci. 1969;5:419–522.PubMed
10.
go back to reference Jialal I, Pillay NL, Asmal AC. Radio-iodine-induced hypoparathyroidism. A case report. S Afr Med J. 1980;58:939–40.PubMed Jialal I, Pillay NL, Asmal AC. Radio-iodine-induced hypoparathyroidism. A case report. S Afr Med J. 1980;58:939–40.PubMed
11.
go back to reference Rosen IB, Palmer JA, Rowen J, Luk SC. Induction of hyperparathyroidism by radioactive iodine. Am J Surg. 1984;148:441–5.PubMedCrossRef Rosen IB, Palmer JA, Rowen J, Luk SC. Induction of hyperparathyroidism by radioactive iodine. Am J Surg. 1984;148:441–5.PubMedCrossRef
12.
go back to reference Esselstyn CB Jr, Schumacher OP, Eversman J, Sheeler L, Levy WJ. Hyperparathyroidism after radioactive iodine therapy for Graves disease. Surgery. 1982;92:811–3.PubMed Esselstyn CB Jr, Schumacher OP, Eversman J, Sheeler L, Levy WJ. Hyperparathyroidism after radioactive iodine therapy for Graves disease. Surgery. 1982;92:811–3.PubMed
13.
go back to reference Holten I, Christiansen C. Unchanged parathyroid function following irradiation for malignancies of the head and neck. Cancer. 1984;53:874–7.PubMedCrossRef Holten I, Christiansen C. Unchanged parathyroid function following irradiation for malignancies of the head and neck. Cancer. 1984;53:874–7.PubMedCrossRef
14.
go back to reference Talmi YP, Wolf GT, Esclamado R, Carroll WR, Sassler AM. Ionized serum calcium levels following combined treatment for cancer of the head and neck. Laryngoscope. 1993;103:1048–51.PubMedCrossRef Talmi YP, Wolf GT, Esclamado R, Carroll WR, Sassler AM. Ionized serum calcium levels following combined treatment for cancer of the head and neck. Laryngoscope. 1993;103:1048–51.PubMedCrossRef
15.
go back to reference Endres DB, Rude RK. Mineral and bone metabolism. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. Missouri: Elsevier & Saunders; 2006. p. 1891–924. Endres DB, Rude RK. Mineral and bone metabolism. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular diagnostics. Missouri: Elsevier & Saunders; 2006. p. 1891–924.
16.
go back to reference Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2:309–10.PubMedCrossRef Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2:309–10.PubMedCrossRef
17.
go back to reference Glazebrook GA. Effect of decicurie doses of radioactive iodine 131 on parathyroid function. Am J Surg. 1987;154:368–73.PubMedCrossRef Glazebrook GA. Effect of decicurie doses of radioactive iodine 131 on parathyroid function. Am J Surg. 1987;154:368–73.PubMedCrossRef
18.
go back to reference Mortensen LS, Smidt K, Jørgensen A, Nielsen JT, Laurberg P, Søndergaard L, et al. Long-term parathyroid- and c-cell function after radioiodine for benign thyroid diseases. Basic Clin Pharmacol Toxicol. 2005;97(1):22–8.PubMedCrossRef Mortensen LS, Smidt K, Jørgensen A, Nielsen JT, Laurberg P, Søndergaard L, et al. Long-term parathyroid- and c-cell function after radioiodine for benign thyroid diseases. Basic Clin Pharmacol Toxicol. 2005;97(1):22–8.PubMedCrossRef
19.
go back to reference Utiger RD. The thyroid: physiology, thyrotoxicosis, hypothyroidism, and the painful thyroid. In: Felig P, Frohman LA, editors. Endocrinology & metabolism. USA: McGraw-Hill; 2001. p. 261–348. Utiger RD. The thyroid: physiology, thyrotoxicosis, hypothyroidism, and the painful thyroid. In: Felig P, Frohman LA, editors. Endocrinology & metabolism. USA: McGraw-Hill; 2001. p. 261–348.
20.
go back to reference Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24:48–77.PubMedCrossRef Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24:48–77.PubMedCrossRef
21.
go back to reference Morgan WF, Sowa MB. Non-targeted bystander effects induced by ionizing radiation. Mutat Res. 2007;616:159–64.PubMed Morgan WF, Sowa MB. Non-targeted bystander effects induced by ionizing radiation. Mutat Res. 2007;616:159–64.PubMed
22.
go back to reference Tzanela M, Thalassinos NC, Nikou A, Georgiadis G, Philokiprou D. Effect of 131I treatment on the calcitonin response to calcium infusion in hyperthyroid patients. Clin Endocrinol (Oxf). 1993;38:25–8.CrossRef Tzanela M, Thalassinos NC, Nikou A, Georgiadis G, Philokiprou D. Effect of 131I treatment on the calcitonin response to calcium infusion in hyperthyroid patients. Clin Endocrinol (Oxf). 1993;38:25–8.CrossRef
23.
go back to reference Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–54.PubMed Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–54.PubMed
24.
go back to reference Gómez N, Gómez JM, Orti A, Gavaldà L, Villabona C, Leyes P, et al. Transient hypothyroidism after iodine-131 therapy for Grave’s disease. J Nucl Med. 1995;36(9):1539–42.PubMed Gómez N, Gómez JM, Orti A, Gavaldà L, Villabona C, Leyes P, et al. Transient hypothyroidism after iodine-131 therapy for Grave’s disease. J Nucl Med. 1995;36(9):1539–42.PubMed
25.
go back to reference Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab. 2005;1:32–40.PubMedCrossRef Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab. 2005;1:32–40.PubMedCrossRef
27.
go back to reference Ogino K, Burkhoff D, Bilezikian JP. The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology. 1995;136:3024–30.PubMedCrossRef Ogino K, Burkhoff D, Bilezikian JP. The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology. 1995;136:3024–30.PubMedCrossRef
Metadata
Title
Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer
Authors
Aytekin Guven
Serpil Salman
Harika Boztepe
Sema Yarman
Refik Tanakol
Halil Azizlerli
Faruk Alagol
Publication date
01-07-2009
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 5/2009
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-009-0270-4

Other articles of this Issue 5/2009

Annals of Nuclear Medicine 5/2009 Go to the issue